DZD Scientist Stephan Herzig Awarded with the Werner Creutzfeldt Prize
For his outstanding achievements in the research field “Diabetes and Cancer”, the German Diabetes Society (DDG) awards this year's Werner Creutzfeldt Prize to Helmholtz Munich scientist Stephan Herzig.
Stephan Herzig is the scientific director of the Helmholtz Diabetes Center and research director of Helmholtz Munich. He also heads the Institute of Diabetes and Cancer at Helmholtz Munich. After his PhD in molecular pharmacology, he started his scientific career as a postdoc at the Salk Institute in the US from 2000 to 2003. From 2004, he established an independent junior research group at the German Cancer Research Center (DKFZ) in Heidelberg. In 2010, he was appointed department head and full Pprofessor of the DKFZ and the medical faculty. In 2015, he moved to Helmholtz Munich, where he remains today. Stephan Herzig holds a chair at the Technical University of Munich (TUM) and is honorary professor at the medical faculty of Heidelberg University.
His research focuses on the molecular basis of metabolic control and the identification of new therapeutic options in diabetes and cancer. He is receiving the Werner Creutzfeldt Prize for his work on “Regulatory and transcriptional networks in diabetes as well as the crosstalk between metabolism and cancer”.
Stephan Herzig has already been awarded numerous prizes: the Marie Curie Excellence Award of the European Union in 2005, the Ferdinand Bertram Prize of the German Diabetes Association in 2007, the Richtzenhain Prize for Translational Cancer Research of the DKFZ in 2010, the Reinhardt Koselleck Prize of the DFG in 2012, and the Research Prize of the German Liver Foundation in 2015.
About the award
The Werner Creutzfeldt Prize of the DDG, endowed with 10,000 euros and donated by the company Lilly Deutschland GmbH, is awarded to researching physicians and scientists for extraordinary work in the field of pathophysiology and therapy of diabetes mellitus, with a special focus on the field of "gastrointestinal hormones".
About Helmholtz Munich
Helmholtz Munich is a leading biomedical research center. Its mission is to develop breakthrough solutions for better health in a rapidly changing world. Interdisciplinary research teams focus on environmentally triggered diseases, especially the therapy and prevention of diabetes, obesity, allergies and chronic lung diseases. With the power of artificial intelligence and bioengineering, the researchers accelerate the translation to patients. Helmholtz Munich has more than 2,500 employees and is headquartered in Munich/Neuherberg. It is a member of the Helmholtz Association, with more than 43,000 employees and 18 research centers the largest scientific organization in Germany. More about Helmholtz Munich (Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH): www.helmholtz-munich.de/en